Navigation Links
Inovio Pharmaceuticals to Present at BioCentury's "Future Leaders in the Biotech Industry" Conference
Date:3/28/2013

BLUE BELL, Pa., March 28, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at the 20th Annual Future Leaders in the Biotech Industry Conference taking place April 5th at the Millennium Broadway Hotel in New York City.

Inovio Presentation
April 5
3:00-3:30 p.m. EDT
A live and archived webcast of the presentation will be available on Inovio's homepage.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

CONTACTS:
Investors: Bernie Hertel , Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson , Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)


'/>"/>
SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
2. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
3. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
4. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
5. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
7. Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
10. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
11. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, ... communities in the greater Chicago metropolitan area, is embarking on a charity drive ... in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & ... to families and business owners in North Central West Virginia, is embarking on ... to differently abled residents in the region. , The Stepping Stones organization offers ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... 2017 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Headquartered in Coconut Creek, Florida, Whipple & Company was ... benefit packages that strengthen the relationship between employer and employee. , “We are ...
Breaking Medicine News(10 mins):